Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MULTICENTER PHASE-II STUDY OF BREQUINAR SODIUM IN PATIENTS WITH ADVANCED BREAST-CANCER
Autore:
CODY R; STEWART D; DEFORNI M; MOORE M; DALLAIRE B; AZARNIA N; GYVES J;
Indirizzi:
DUPONT PHARMACEUT CO,POB 80026 WILMINGTON DE 19880 DUPONT PHARMACEUT CO,POB 80026 WILMINGTON DE 19880 OTTAWA REG CANC CTR OTTAWA ON CANADA UNIV MICHIGAN ANN ARBOR MI 48109 CTR CLAUDIUS REGAUD F-31052 TOULOUSE FRANCE PRINCESS MARGARET HOSP TORONTO M4X 1K9 ONTARIO CANADA
Titolo Testata:
American journal of clinical oncology
fascicolo: 6, volume: 16, anno: 1993,
pagine: 526 - 528
SICI:
0277-3732(1993)16:6<526:MPSOBS>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
NSC 368390; DUP 785; NSC-368390; TUMORS; TRIAL; ACID; SALT;
Keywords:
BREAST CANCER; BREQUINAR SODIUM; PHASE-II;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
10
Recensione:
Indirizzi per estratti:
Citazione:
R. Cody et al., "MULTICENTER PHASE-II STUDY OF BREQUINAR SODIUM IN PATIENTS WITH ADVANCED BREAST-CANCER", American journal of clinical oncology, 16(6), 1993, pp. 526-528

Abstract

In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were postmenopausal, and 94%had received chemotherapy previously; 50% had previously received an anthracycline-containing regimen. Brequinar was administered intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 17 patients (50%) experiencing grade 3 or 4 toxicity. There were 33 patients evaluable for response: 4 patients (12%; 95% confidence interval, 3.4-28.2%) achieved partial responses, 10 patients (30%) were stable, and 19 patients (58%) had progressive disease. We conclude that. at this dose and schedule, brequinar has only modest activity in patients with advanced breast cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 19:39:40